XNASADAP
Market cap25mUSD
Dec 23, Last price
0.59USD
1D
-2.79%
1Q
-39.44%
Jan 2017
-85.48%
IPO
-96.59%
Name
Adaptimmune Therapeutics PLC
Chart & Performance
P/E
—
P/S
2.50
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.60%
Rev. gr., 5y
0.26%
Revenues
60m
+122.05%
Net income
-114m
L-31.18%
CFO
-141m
L-0.63%
Earnings
May 14, 2025
Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑06 | |
| Income | |||||||||
Revenues | 60,281 122.05% | 27,148 341.50% | 6,149 55.36% | ||||||
Cost of revenue | 208,176 | 318,839 | 279,485 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (147,895) | (291,691) | (273,336) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,336 | 2,497 | 791 | ||||||
Tax Rate | |||||||||
NOPAT | (149,231) | (294,188) | (274,127) | ||||||
Net income | (113,871) -31.18% | (165,456) 4.66% | (158,090) 21.52% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 624 | 12,817 | 3,288 | ||||||
BB yield | -2.35% | -32.67% | -3.38% | ||||||
| Debt | |||||||||
Debt current | 10,768 | 2,728 | 2,320 | ||||||
Long-term debt | 64,937 | 43,426 | 48,616 | ||||||
Deferred revenue | 149,060 | 160,892 | 177,223 | ||||||
Other long-term liabilities | (18,447) | 1,296 | 673 | ||||||
Net debt | (71,233) | (160,020) | (320,362) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (140,880) | (141,769) | 10,729 | ||||||
CAPEX | (4,681) | (29,740) | (8,781) | ||||||
Cash from investing activities | 176,538 | 89,137 | 75,800 | ||||||
Cash from financing activities | 880 | 12,867 | 3,288 | ||||||
FCF | (149,404) | (314,354) | (278,838) | ||||||
| Balance | |||||||||
Cash | 146,938 | 204,605 | 369,580 | ||||||
Long term investments | 1,569 | 1,718 | |||||||
Excess cash | 143,924 | 204,817 | 370,991 | ||||||
Stockholders' equity | (1,025,056) | (908,778) | (753,651) | ||||||
Invested Capital | 1,265,503 | 1,175,921 | 1,162,975 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 201,073 | 161,207 | 155,806 | ||||||
Price | 0.13 -45.68% | 0.24 -61.07% | 0.63 -30.43% | ||||||
Market cap | 26,575 -32.25% | 39,227 -59.72% | 97,378 -23.91% | ||||||
EV | (44,658) | (120,793) | (222,984) | ||||||
EBITDA | (138,442) | (285,616) | (266,769) | ||||||
EV/EBITDA | 0.32 | 0.42 | 0.84 | ||||||
Interest | 1,006 | ||||||||
Interest/NOPBT | |||||||||